Shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Get Free Report) rose 2.1% during mid-day trading on Friday. The company traded as high as $1.97 and last traded at $1.95. Approximately 38,594 shares changed hands during trading, an increase of 21% from the average daily volume of 31,766 shares. The stock had previously closed at $1.91.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cardio Diagnostics in a report on Tuesday, September 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Cardio Diagnostics presently has a consensus rating of “Sell”.
View Our Latest Analysis on CDIO
Cardio Diagnostics Price Performance
Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.51) EPS for the quarter. Cardio Diagnostics had a negative return on equity of 82.28% and a negative net margin of 43,133.33%.The company had revenue of $0.01 million for the quarter.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Cardio Diagnostics stock. Renaissance Technologies LLC bought a new position in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 15,348 shares of the company’s stock, valued at approximately $30,000. Renaissance Technologies LLC owned about 0.52% of Cardio Diagnostics at the end of the most recent quarter. Hedge funds and other institutional investors own 8.06% of the company’s stock.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc is a biotechnology and medical technology company focused on the prevention and early detection of cardiovascular disease. The company combines artificial intelligence with genetic and epigenetic data to develop personalized tools intended to help identify cardiovascular risk and support more targeted care.
Its products include Epi+Gen CHD, a blood-based test designed to assess an individual’s risk of developing coronary heart disease, and PrecisionCHD, which is intended to help identify the presence of coronary heart disease.
Read More
- Five stocks we like better than Cardio Diagnostics
- 3 Defense Stocks Riding Nuclear, Missile, and Aerospace Demand
- SoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement
- These 3 Overlooked Stocks Have Big Money Behind Them
- Darden Restaurants Serves Up Fresh Catalysts for a Stock Price Rally
Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
